Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALGRX 3268 is a novel, single-use, prefilled, needle-free drug delivery system designed to provide rapid local anesthesia for minor procedures such as venipuncture and intravenous line placement. The device delivers powdered lidocaine into the epidermis using a gas-powered injector (PowderJect technology), achieving local analgesia within approximately one to three minutes. This fast onset distinguishes it from traditional topical anesthetics that require significantly longer application times. The product was primarily developed for pediatric patients but may also be useful in adult emergency settings and other clinical environments where quick pain relief is needed before needle insertion. Clinical trials demonstrated that ALGRX 3268 significantly reduces pain associated with needlestick procedures compared to placebo and is well tolerated with no significant safety issues[1][2][4][5][6][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ALGRX 3268.